COVID-19 Among Patients With Inflammatory Rheumatic Diseases

Autor: Sinem Nihal Esatoglu, Koray Tascilar, Hakan Babaoğlu, Cemal Bes, Berna Yurttas, Servet Akar, Ozlem Pehlivan, Cansu Akleylek, Duygu Tecer, Emire Seyahi, Tuba Yuce-Inel, Nilufer Alpay-Kanitez, Erdal Bodakci, Emre Tekgoz, Seda Colak, Ertugrul Cagri Bolek, Suleyman Serdar Koca, Umut Kalyoncu, Ozan Cemal Icacan, Serdal Ugurlu, Hande Ece Oz, Vedat Hamuryudan, Gulen Hatemi, the Turkish Society for Rheumatology COVID-19 Registry Investigators, Ayse Cefle, Ali Karakas, Derya Kaskari, Samet Karahan, Dilek Tezcan, Abdurrahman Tufan, Ayse Ayan, Levent Kılıc, Salim Donmez, Mustafa Erdogan, Veli Yazisiz, Edip Gokalp Gok, Ahmet Eftal Yucel, Elif Dincses Nas, Gezmiş Kimyon, Gunay Sahin Dalgic, Hakan Erdem, Kerem Yigit Abacar, Ridvan Mercan, Omer Karadag, Onay Gercik, Suleyman Ozbek, Sebnem Gider, Semih Gulle, Sibel Osken, Sedat Kiraz, Timucin Kasifoglu, Fatma Alibaz-Oner, Izzet Fresko, Ali Akdogan, Neslihan Yilmaz

Publikováno v: Frontiers in Immunology, Vol 12 (2021)

BackgroundThe course of novel coronavirus disease 2019 (COVID-19) has been of special concern in patients with inflammatory rheumatic diseases (IRDs) due to the immune dysregulation that may be associated with these diseases and the medications used

Externí odkaz: https://doaj.org/article/4de36d4dba664dd2ae34873a6dca683e

Current pharmacological solutions for Behçet’s syndrome

Autor: Yesim Ozguler, Sinem Nihal Esatoglu, Gulen Hatemi

Publikováno v: Expert Opinion on Pharmacotherapy. 24:221-231

Behçet's syndrome (BS) has a heterogeneous clinical phenotype and clinical manifestations may respond differently to drugs commonly used to treat BS. The type, dose and duration of immunomodulatory, immunosuppressive and biologic agents should be ta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60631ad07c8a99a6a2491fadc31a8949
https://doi.org/10.1080/14656566.2022.2155047

Frequency of AA amyloidosis has decreased in Behçet’s syndrome: a retrospective study with long-term follow-up and a systematic review

Autor: Guzin Karatemiz, Sinem Nihal Esatoglu, Mert Gurcan, Yesim Ozguler, Sebahattin Yurdakul, Vedat Hamuryudan, Izzet Fresko, Melike Melikoglu, Emire Seyahi, Serdal Ugurlu, Huri Ozdogan, Hasan Yazici, Gulen Hatemi

Publikováno v: Rheumatology. 62:9-18

Objective A decline in the frequency of AA amyloidosis secondary to RA and infectious diseases has been reported. We aimed to determine the change in the frequency of AA amyloidosis in our Behçet’s syndrome (BS) patients and to summarize the clini

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81baf669a5d117f4f1f8b3b918a633e3
https://doi.org/10.1093/rheumatology/keac223

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis

Autor: Richard Watts, Vladimir Tesar, Wolfgang Schmidt, Rebecca Grainger, Omer Karadag, Peter Lamprecht, Cristina Ponte, Peter Merkel, Elsa Azevedo, David Jayne, Andrew Hutchings, Andrew Judge, Hajime Kono, Gulen Hatemi, Justin Mason, Nevin Hammam

Publikováno v: Robson, J C, Grayson, P, Ponte, C, Suppiah, R, Craven, A, Judge, A, Khalid, S, Hutchings, A, Watts, R, Merkel, P & Luqmani, R A 2022, ' 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis ', Arthritis and Rheumatology, vol. 74, no. 3, pp. 393–399 . https://doi.org/10.1002/art.41986
Robson, J C, Grayson, P, Ponte, C, Suppiah, R, Craven, A, Judge, A, Khalid, S, Hutchings, A, Watts, R, Merkel, P & Luqmani, R A 2022, ' 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis ', Annals of the Rheumatic Diseases, vol. 81, no. 3, 221795, pp. 315-320 . https://doi.org/10.1136/annrheumdis-2021-221795
Arthritis and Rheumatology, 74(3), 393-399. Wiley

ObjectiveTo develop and validate revised classification criteria for granulomatosis with polyangiitis (GPA).MethodsPatients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in five phases: (1) id

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2a77c6ab76c6c37d24c3ef5cb251456
https://hdl.handle.net/11370/11792586-362a-4141-bc31-85c1d006abef

Treat to target in Behcet's disease

Autor: George E. Fragoulis, George Bertsias, Bahram Bodaghi, Ahmet Gul, Jan van Laar, Gonca Mumcu, David Saadoun, Ilknur Tugal-Tutkun, Gulen Hatemi, Petros P. Sfikakis

Publikováno v: Clinical Immunology, 246:109186. Academic Press

During the last decades the efficacy of biologic agents, mainly of anti-TNFs, in controlling the activity of serious manifestations of Behcet's Disease (BD) has been established. On the other hand, the clinical heterogeneity of BD has precluded the v

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5b51eed81daa27186e2dfadde7a5fa4
https://pure.eur.nl/en/publications/9150d9ba-c8d9-4d49-a267-1ef2f4a9d4c3